The CD16+CD56+ NK-cell level before the first dose was higher in volunteers without NAb titers than in those who achieved NAbs 3 weeks after the second COVID-19 vaccination (Figure 3A, p < 0.05). This evidence concerns the gene NCAM1 and COVID-19.